CAR-NK Cell Therapy for Advanced Gastric Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed as unresectable (cannot be surgically removed) or metastatic (spread to other parts of your body)
- Your tumor must test positive for CLDN18.2 protein (a marker on at least 10% of your cancer cells) and HER2 status must be determined
- Your cancer must have progressed despite at least 2 prior chemotherapy treatments
- You must have at least one measurable tumor on imaging scans
- Your overall health and organ function must be adequate, and you must have a life expectancy of at least 12 weeks
- You cannot be pregnant or breastfeeding, and must agree to use contraception during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
This trial tests a new treatment using modified natural killer cells (CAR-NK) that target two specific proteins found on your cancer cells. It is for people with advanced colorectal cancer who have tried standard treatments without success.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Hear when a new Advanced Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.